In an effort to produce new lead antimycobacterial compounds, herein we have reported the synthesis of a sequence of new pyrrolyl benzamide derivatives. The new chemical entities were screened to target enoyl-ACP reductase enzyme, which is one of the key enzymes of M. tuberculosis that are involved in type II fatty acid biosynthetic pathway. Compound 3q exhibited H-bonding interactions with Tyr158, Thr196 and co-factor NAD⁺ that binds the active site of InhA. All the pyrrolyl benzamide compounds were evaluated as inhibitors of M. tuberculosis H₃₇Rv as well as inhibitors of InhA. Among them, few representative compounds were tested for mammalian cell toxicity on the human lung cancer cell-line (A549) and MV cell line that presented no cytotoxicity. Five of these compounds exhibited a good activity against InhA.

为了生产新的抗分枝杆菌先导化合物，本文中我们报道了新的吡咯基苯甲酰胺衍生物序列的合成。筛选了新的化学实体以靶向烯酰基-ACP还原酶，该酶是参与II型脂肪酸生物合成途径的结核分枝杆菌的关键酶之一。化合物3q与Tyr158，Thr196和与InhA活性位点结合的辅因子NAD ⁺表现出H键相互作用。所有吡咯基苯甲酰胺化合物均被评估为结核分枝杆菌H _37的抑制剂Rv和InhA抑制剂。其中，很少有代表性的化合物对未表现出细胞毒性的人肺癌细胞系（A549）和MV细胞系进行哺乳动物细胞毒性测试。这些化合物中的五个对InhA表现出良好的活性。